| Added by | André Pèlegrin |
|---|---|
| Last modified by | standudu |
| Group name | EquipeAP |
| Item Type | Journal Article |
| Title | Concurrent or sequential letrozole with adjuvant breast radiotherapy: Final results of the CO-HO-RT phase II randomized trial |
| Creator | Bourgier et al. |
| Author | C. Bourgier |
| Author | S. Kerns |
| Author | S. Gourgou |
| Author | C. Lemanski |
| Author | M. Gutowski |
| Author | P. Fenoglietto |
| Author | G. Romieu |
| Author | N. Crompton |
| Author | J. Lacombe |
| Author | M. Ozsahin |
| Author | B. Rosenstein |
| Author | D. Azria |
| Abstract | BACKGROUND: We present here final clinical results of the COHORT trial and both translational sub-studies aiming at identifying patients at risk of radiation-induced subcutaneous fibrosis (RISF): (i) radiation-induced lymphocyte apoptosis (RILA) and (ii) candidates of certain single nucleotide polymorphisms (SNP). PATIENTS AND METHODS: Postmenopausal patients with stage I-II breast cancer (n=150) were enrolled and assigned to either concurrent (arm A) or sequential radiotherapy-letrozole (arm B). Among them, 121 were eligible for RILA and SNP assays. Grade ?2 RISF were the primary endpoint. Secondary endpoints were lung and heart events and carcinologic outcome. RILA was performed to predict differences in RISF between individuals. A genome-wide association study was performed to identify SNPs associated with RILA and RISF. Analyses were done by intention to treat. RESULTS: After a median follow-up of 74 months, 5 patients developed a grade ?2 RISF. No significant difference was observed between arms A and B. Neither grade ?2 lung nor symptomatic cardiac toxicity was observed. Median RILA value of the five patients who had grade ?2 RISF was significantly lower compared to those who developed grade ?1 RISF (6.9% vs 13%, p=0.02). Two SNPs were identified as being significantly associated with RILA: rs1182531 (p=4.2x10(-9)) and rs1182532 (p=3.6x10(-8)); both located within the PHACTR3 gene on chromosome 20q13.33. CONCLUSIONS: With long-term follow-up, letrozole can safely be delivered concomitantly with adjuvant breast radiotherapy. Translational sub-studies showed that high RILA values were correlated with patients who did not develop RISF. REGISTERED CLINICAL TRIAL: NCT00208273. |
| Publication | Annals of oncology: official journal of the European Society for Medical Oncology / ESMO |
| Date | Dec 17, 2015 |
| Journal Abbr | Ann. Oncol. |
| Language | ENG |
| DOI | 10.1093/annonc/mdv602 |
| ISSN | 1569-8041 |
| Short Title | Concurrent or sequential letrozole with adjuvant breast radiotherapy |
| Library Catalog | PubMed |
| Extra | PMID: 26681684 |
| Tags | breast cancer, clinic, Equipe, original, Radiation-induced late effects, radio-hormonotherapy |
| Date Added | 2019/12/12 - 17:37:59 |
| Date Modified | 2020/01/09 - 18:10:22 |
| Notes and Attachments | PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
